IL146868A0 - A pharmaceutical composition containing an igf-i/igfbp-3 complex - Google Patents

A pharmaceutical composition containing an igf-i/igfbp-3 complex

Info

Publication number
IL146868A0
IL146868A0 IL14686800A IL14686800A IL146868A0 IL 146868 A0 IL146868 A0 IL 146868A0 IL 14686800 A IL14686800 A IL 14686800A IL 14686800 A IL14686800 A IL 14686800A IL 146868 A0 IL146868 A0 IL 146868A0
Authority
IL
Israel
Prior art keywords
igfbp
complex
type
igf
pharmaceutical composition
Prior art date
Application number
IL14686800A
Other languages
English (en)
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of IL146868A0 publication Critical patent/IL146868A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14686800A 1999-06-04 2000-05-23 A pharmaceutical composition containing an igf-i/igfbp-3 complex IL146868A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
IL146868A0 true IL146868A0 (en) 2002-08-14

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14686800A IL146868A0 (en) 1999-06-04 2000-05-23 A pharmaceutical composition containing an igf-i/igfbp-3 complex

Country Status (16)

Country Link
US (1) US6040292A (es)
EP (1) EP1183042B1 (es)
JP (1) JP2003501397A (es)
KR (1) KR100694737B1 (es)
CN (1) CN1235637C (es)
AT (1) ATE271880T1 (es)
AU (1) AU780400B2 (es)
CA (1) CA2373281C (es)
DE (1) DE60012517T2 (es)
ES (1) ES2222208T3 (es)
HK (1) HK1044895A1 (es)
IL (1) IL146868A0 (es)
MX (1) MXPA01013384A (es)
NO (1) NO324117B1 (es)
WO (1) WO2000074710A2 (es)
ZA (1) ZA200110408B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MY137552A (en) * 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20080268093A1 (en) * 2004-12-30 2008-10-30 Eric Vaun Bowman Compositions For Feline Consumption
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
US8404639B2 (en) 2008-10-29 2013-03-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
JP5795306B2 (ja) 2009-04-01 2015-10-14 ジェネンテック， インコーポレイテッド インスリン抵抗性疾患の治療
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
HUE038366T2 (hu) * 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
EP0642350A4 (en) * 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE190499T1 (de) * 1993-08-03 2000-04-15 Celtrix Pharma Methode zur behandlung von reproduktionserkrankungen
ATE226958T1 (de) * 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
WO1995013824A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering igf-i and igfbp-3
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
JPH10512235A (ja) * 1994-07-20 1998-11-24 セルトリックス ファーマシューティカルズ，インコーポレイテッド 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
CN1387440A (zh) 2002-12-25
NO20015932D0 (no) 2001-12-04
CA2373281C (en) 2010-01-12
CA2373281A1 (en) 2000-12-14
KR100694737B1 (ko) 2007-03-14
EP1183042A2 (en) 2002-03-06
CN1235637C (zh) 2006-01-11
NO20015932L (no) 2002-01-31
JP2003501397A (ja) 2003-01-14
DE60012517D1 (de) 2004-09-02
ES2222208T3 (es) 2005-02-01
US6040292A (en) 2000-03-21
ZA200110408B (en) 2003-03-19
NO324117B1 (no) 2007-08-27
ATE271880T1 (de) 2004-08-15
WO2000074710A2 (en) 2000-12-14
AU5041100A (en) 2000-12-28
KR20020020723A (ko) 2002-03-15
EP1183042B1 (en) 2004-07-28
HK1044895A1 (en) 2002-11-08
AU780400B2 (en) 2005-03-17
MXPA01013384A (es) 2003-09-04
WO2000074710A3 (en) 2001-06-28
DE60012517T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
IL146868A0 (en) A pharmaceutical composition containing an igf-i/igfbp-3 complex
HUT68525A (en) Pharmaceutical compositions of prolonged delivery, containing peptides
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
EP0997151A3 (en) Method for administering insulinotropic peptides
PL322450A1 (en) Pharmaceutic composition containing selected lanthanum carbonate hydrates
DE68929217D1 (en) Insulinotropes hormon
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
AU3432295A (en) Glucagon-like insulinotropic peptide analogs compositions, and methods of use
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
WO2003053339A3 (en) Insulin molecule having protracted time action
NO940180D0 (no) Anvendelse av IGF-I
CA2270177A1 (en) Transdermal administration of ment
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
CA2252560A1 (en) Treatment of partial growth hormone insensitivity syndrome
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP982534A (es) Nuevo metodo de tratamiento
ECSP982542A (es) Nuevo metodo de tratamiento iii
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees